Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Indirect treatment comparison of brexucabtagene autoleucel (ZUMA-2) versus standard of care (SCHOLAR-2) in relapsed/refractory mantle cell lymphoma

Hess, Georg ; Dreyling, Martin ; Oberic, Lucie ; Gine, Eva ; Zinzani, Pier Luigi ; Linton, Kim ; Vilmar, Adam ; Jerkeman, Mats LU ; Chen, Jenny M.H. and Ohler, Anke , et al. (2023) In Leukemia and Lymphoma
Abstract

The SCHOLAR-2 retrospective study highlighted poor overall survival (OS) with standard of care (SOC) regimens among patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) who failed a covalent Bruton tyrosine kinase inhibitor (BTKi). In the ZUMA-2 single-arm trial, brexucabtagene autoleucel (brexu-cel; autologous anti-CD19 CAR T-cell therapy) demonstrated high rates of durable responses in patients with R/R MCL who had previous BTKi exposure. Here, we compared OS in ZUMA-2 and SCHOLAR-2 using three different methods which adjusted for imbalances in prognostic factors between populations: inverse probability weighting (IPW), regression adjustment (RA), and doubly robust (DR). Brexu-cel was associated with improved OS compared... (More)

The SCHOLAR-2 retrospective study highlighted poor overall survival (OS) with standard of care (SOC) regimens among patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) who failed a covalent Bruton tyrosine kinase inhibitor (BTKi). In the ZUMA-2 single-arm trial, brexucabtagene autoleucel (brexu-cel; autologous anti-CD19 CAR T-cell therapy) demonstrated high rates of durable responses in patients with R/R MCL who had previous BTKi exposure. Here, we compared OS in ZUMA-2 and SCHOLAR-2 using three different methods which adjusted for imbalances in prognostic factors between populations: inverse probability weighting (IPW), regression adjustment (RA), and doubly robust (DR). Brexu-cel was associated with improved OS compared to SOC across all unadjusted and adjusted comparisons. Hazard ratios (95% confidence intervals) were 0.38 (0.23, 0.61) for IPW, 0.45 (0.28, 0.74) for RA, and 0.37 (0.23, 0.59) for DR. These results suggest a substantial survival benefit with brexu-cel versus SOC in patients with R/R MCL after BTKi exposure.

(Less)
Please use this url to cite or link to this publication:
author
; ; ; ; ; ; ; ; and , et al. (More)
; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; and (Less)
organization
publishing date
type
Contribution to journal
publication status
epub
subject
keywords
brexucabtagene autoleucel, CAR T-cell therapy, indirect treatment comparison, mantle cell lymphoma, non-Hodgkin lymphoma, standard of care
in
Leukemia and Lymphoma
publisher
Taylor & Francis
external identifiers
  • pmid:37840282
  • scopus:85174242231
ISSN
1042-8194
DOI
10.1080/10428194.2023.2268228
language
English
LU publication?
yes
additional info
Publisher Copyright: © 2023 Kite Pharma. Published by Informa UK Limited, trading as Taylor & Francis Group.
id
e5ec2026-68b4-45f8-9b07-27a18b131ec3
date added to LUP
2023-12-20 16:09:55
date last changed
2024-04-19 01:40:18
@article{e5ec2026-68b4-45f8-9b07-27a18b131ec3,
  abstract     = {{<p>The SCHOLAR-2 retrospective study highlighted poor overall survival (OS) with standard of care (SOC) regimens among patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) who failed a covalent Bruton tyrosine kinase inhibitor (BTKi). In the ZUMA-2 single-arm trial, brexucabtagene autoleucel (brexu-cel; autologous anti-CD19 CAR T-cell therapy) demonstrated high rates of durable responses in patients with R/R MCL who had previous BTKi exposure. Here, we compared OS in ZUMA-2 and SCHOLAR-2 using three different methods which adjusted for imbalances in prognostic factors between populations: inverse probability weighting (IPW), regression adjustment (RA), and doubly robust (DR). Brexu-cel was associated with improved OS compared to SOC across all unadjusted and adjusted comparisons. Hazard ratios (95% confidence intervals) were 0.38 (0.23, 0.61) for IPW, 0.45 (0.28, 0.74) for RA, and 0.37 (0.23, 0.59) for DR. These results suggest a substantial survival benefit with brexu-cel versus SOC in patients with R/R MCL after BTKi exposure.</p>}},
  author       = {{Hess, Georg and Dreyling, Martin and Oberic, Lucie and Gine, Eva and Zinzani, Pier Luigi and Linton, Kim and Vilmar, Adam and Jerkeman, Mats and Chen, Jenny M.H. and Ohler, Anke and Stilgenbauer, Stephan and Thieblemont, Catherine and Lambert, Jonathan and Zilioli, Vittorio Ruggero and Sancho, Juan Manuel and Jimenez-Ubieto, Ana and Fischer, Luca and Eyre, Toby A. and Keeping, Sam and Park, Julie E. and Wu, James J. and Nunes, Ana and Reitan, John and Wade, Sally W. and Salles, Gilles}},
  issn         = {{1042-8194}},
  keywords     = {{brexucabtagene autoleucel; CAR T-cell therapy; indirect treatment comparison; mantle cell lymphoma; non-Hodgkin lymphoma; standard of care}},
  language     = {{eng}},
  publisher    = {{Taylor & Francis}},
  series       = {{Leukemia and Lymphoma}},
  title        = {{Indirect treatment comparison of brexucabtagene autoleucel (ZUMA-2) versus standard of care (SCHOLAR-2) in relapsed/refractory mantle cell lymphoma}},
  url          = {{http://dx.doi.org/10.1080/10428194.2023.2268228}},
  doi          = {{10.1080/10428194.2023.2268228}},
  year         = {{2023}},
}